That's what Eli Lilly did. It ran a phase 3b trial where some patients living with obesity were given tirzepatide (the active ingredient in Zepbound) while others received semaglutide (the active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback